Lupin in in-licensing agreement with Italian pharma major

Mumbai, May 15 (UNI) Mumbai-headquartered pharma major Lupin Limited has inked an in-licensing agreement with Italy-based ItalFarmaco by which Lupin will exclusively market the latter's cardiovascular critical care product called enoxaparin sodium injection under the brand name ''Lupenox'' in the Indian market.

A press release issued here today stated that Lupenox will be marketed in pre-filled syringes.

Commenting on the tie-up, Mr Sakti Chakraborty, President-India Region Formulations, Lupin, said that ''in life-critical situations, quality is of paramount importance and we believe that Lupenox, being a superior quality product sourced from ItalFarmaco's USFDA-approved facility, will serve the needs of patients better.'' UNI JJ PM SKB1805